Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sedana Medical enters China – signs with Chinese distributor

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced a 10-year exclusive distribution agreement with the Chinese distributor Kyuan Xinhai Medical, a subsidiary of partly state-owned Shanghai Pharma, the second largest life science company in China. Kyuan will immediately commence the fast-track registration of AnaConDa in China and estimates approval will be obtained in less than two years. The Chinese market potential for sedation in intensive care is estimated to be five to six million ventilation days annually.Kyuan is making a major investment in this cooperation which

Stora Enso: Managers’ transactions – Jorma Eloranta

STORA ENSO OYJ MANAGERS’ TRANSACTIONS 3 June 2019 at 9.30 EESTStora Enso Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Eloranta, Jorma Position: Member of the Board/Deputy member Issuer: Stora Enso Oyj LEI: 7437000ZP669LKUTZ738 Notification type: INITIAL NOTIFICATION Reference number: 7437000ZP669LKUTZ738_20190603081355_2 ____________________________________________ Transaction date: 2019-05-31 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009005961

New data from the phase I study of birinapant in combination with Keytruda® presented at ASCO

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase I study of birinapant in combination with pembrolizumab (Keytruda®) was presented at an oral session on June 2nd at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, USA. The data was presented by Dr. Russel J. Schilder, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, USA. The efficacy of the combination treatment is explored in patients with different advanced solid tumors who do not have further available treatment options. The

Press invitation: How can we solve the problem of ocean plastic?

The ocean is the final destination for large amounts of plastic, but how dangerous is this and what can we do about it? This is the theme of a scientific symposium at which the Royal Academy of Sciences and the International Union for Conservation of Nature (IUCN) will gather expertise in the field.The problem of ocean plastic has recently been receiving a great deal of attention. We know that there are large amounts of plastic in our oceans, and it is estimated that about twelve million tons end up there every year. This is equivalent to more than 22 tons per minute, 24 hours a day. Around

Fixfabriken breathes new life into Majorna

Williamsburg in New York, Shoreditch in London and Belleville in Paris are three examples of city districts that have become red hot destinations for urban tourists from all over the world. It will be a while before Majorna in Gothenburg can measure up to the competition, but with Fixfabriken leading the way, urban renewal is now in progress.“There are too few people in Majorna today, we need to breathe new life into the district which has stagnated and become a bit one-dimensional,” thinks Björn Siesjö, City Architect in Gothenburg. The spade will soon be put in the ground for the new

Bactiguard enters new partnership for Switzerland

Bactiguard has entered a new partnership with Euromed Swiss AG (Euromed), a leading, specialized Swiss distributor of medical devices. Euromed will be distributing the entire Bactiguard product portfolio for infection prevention in Switzerland."By working with Euromed and their experienced, professional team, we will increase the pace of our European market expansion. Euromed is a leading provider of medical devices to both public and private hospitals and we are convinced that they have the competence and the resources needed to offer advanced solutions and drive Bactiguard's sales in

InDex Pharmaceuticals presents at Redeye Growth Day on June 10, 2019

June 3, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Growth Day at Haymarket by Scandic, Hötorget 13-15, in Stockholm on June 10 at 14.40 CET. The presentation will be livestreamed and can be followed at www.redeye.se/live/redeye-growth-day-19.The presentation will also be available afterwards at www.redeye.se/live/redeye-growth-day-19, on the company’s page in Redeye Universe (www.redeye.se/company/index-pharmaceuticals), as well as on the company’s website (www.indexpharma.com). For more information:Peter

Lynparza nearly doubled time patients lived with

Lynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer 22% of patients receiving Lynparza remained free ofdisease progression after two years vs. 10% on placebo Lynparza now the first PARP inhibitor todemonstrate benefit in three different cancer types 3 June 2019 07:00 BST AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced detailed results from the Phase III POLO trial at the 2019 American Society of Clinical Oncology (ASCO)

Tele2 and Bite sign agreement to share networks in Latvia and Lithuania

Stockholm – Tele2 AB (Tele2) (Nasdaq Stockholm: TEL2 A and TEL2 B) has today signed an agreement with the operator Bite to create a network sharing joint venture in Latvia and Lithuania. The partnership includes sharing of infrastructure in current networks, spectrum sharing as well as future build-out of 5G.Tele2 and Bite have today signed an agreement to create a joint venture with the mission to build, own and operate mobile networks in Latvia and Lithuania. The partnership includes sharing of active and passive network infrastructure and transmission for 2G, 3G, 4G as well as the

Metsähallitus and CollectiveCrunch announce partnership to bring AI to forestry

The ambitious co-operation, based on an innovation partnership, targets the development, planning and usage of 5 million hectares of forest landTech company CollectiveCrunch  and Metsähallitus Forestry Ltd., the subsidiary of Finnish state-owned land and forest management enterprise Metsähallitus  have entered into an innovation partnership with the goal of improving harvesting and forest development planning through deep artificial intelligence (AI) technology and big data analysis. The organizations will develop new forestry tools

Redeye initiates coverage of Ranplan Group

Redeye initiates coverage of Ranplan, a provider of wireless network planning and optimisation software. Through its unique offering with combined support for both indoor and outdoor networks, we argue that Ranplan is well-positioned to deliver significant growth over the coming years. There is further high operating leverage in the business model, which allows for strong profitability. We see substantial upside potential in the share and expect the company's growth performance to earn greater attention from investors going forward. Read more and download the research update: http://bit.

Loudspring Oyj - Manager's Transactions

Loudspring Oyj Company Release 3 June 2019 at 8.30 (EEST) ____________________________________________ Person subject to the notification requirement Name: Vuoria, Matti Position: Chairman of the Board Issuer: Loudspring Oyj LEI: 74370040F0RYWDWUJC65 Notification type: Initial notification Reference number: 74370040F0RYWDWUJC65_20190531135757_2 ____________________________________________ Transaction date: 2019-05-31 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: Share ISIN: FI4000092523 Nature of the transaction: ACQUISITION

Share buy-backs in Telia Company during week 22 2019

During the period May 27, 2019, until May 31, 2019, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 2,150,196 own shares (ISIN: SE0000667925).The share buy-backs form part of the SEK 5 billion share buy-back program that Telia Company announced on April 16, 2019. The share buy-back program, which runs between April 16, 2019, and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period May 27,

Monica Söderlund appointed as the Managing Director of Fondia Sweden

Fondia Plc Press release June 3rd, 2019 8.00 Ms. Monica Söderlund, LL.M, has been appointed as the Managing Director of Fondia Plc’s Swedish subsidiary Fondia Legal Services AB. Previously, Monica was with Grant Thornton, where she acted as Head of Tax Sweden, Partner, and as member of the Management Board as well as the Global Tax Advisory Board. Monica will start in her new position at Fondia Legal Services AB on June 10th, 2019. At Fondia, she will join the Group Management Team alongside the Fondia Sweden’s Leadership Team. As informed earlier in a company release, the

Pihlajalinna Plc and Pohjola Insurance Ltd to pilot cooperation in two municipalities

Pihlajalinna Plc                   Inside information               3 June 2019 at 8.00 Pihlajalinna Plc and Pohjola Insurance Ltd (OP Insurance Ltd until 31 May) have, on 31 May 2019, signed a cooperation agreement aiming to pilot a new kind of customer service model for the customers of Pohjola Insurance Ltd in two municipalities.  Further information:  Rami Mäkinen, Director, Pohjola Insurance Ltd, tel. +358 (0)50 361 7706, rami.makinen@pohjola.fiTeija Kulmala, Head of Business Operations, Mid-Finland, Pihlajalinna Plc, tel. +358 (0)50 347 4661, teija.kulmala@pihlajalinna.fi

Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination

·  Combination of ONCOS-102 and Keytruda reduces size of non-injected tumors   ·  In vivo proof-of-concept of ONCOS-102 ability to generate systemic anti-tumor responses  Oslo, Norway, 3 June 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a humanized mouse melanoma model has been accepted for publication in the Journal of Medical Virology.  Targovax has previously published anti-tumor

Nordic Nanovector: European patent granted for Betalutin® or Humalutin® in combination with anti-CD20 antibodies for treating NHL

Oslo, Norway 3 June 2019 Nordic Nanovector ASA (OSE: NANO) announces that the European Patent Organisation (EPO) has granted the company’s European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20 antibodies for the treatment of non-Hodgkin’s lymphoma (NHL). The same patent has also been issued in Japan, China, Australia, Hong Kong, Israel, Russia and Singapore while the patent is pending in USA, Brazil, Canada, Indonesia, India, Korea, Mexico, New Zealand, Philippines, Ukraine and South Africa. This patent is a result of Nordic Nanovector’s continued

Cantargia: presentation of phase I clinical data on antibody CAN04 at ASCO

New phase I clinical data on Cantargia´s antibody CAN04 (nidanilimab) were presented today in an oral session at the 2019 ASCO Annual Meeting. Data from 22 patients show that CAN04 treatment has a good safety profile. Most patients treated got a decrease in the biomarkers IL-6 and CRP already after two weeks of therapy. Nine patients had stable disease for at least 8 weeks. One patient with non-small cell lung cancer (NSCLC) progressed after 31 weeks and one patient with pancreatic cancer (PDAC) after 24 weeks. The results can be accessed through Cantargias webpage www.cantargia.com and are

BerGenBio presents new preliminary clinical and biomarker data showing durable response & median survival rates in Phase II trial with bemcentinib and KEYTRUDA in pts with advanced NSCLC at ASCO 2019

· Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy · Promising clinical activity continues to be seen, particularly in patients with AXL positive tumours including those with low or no PD-L1 expressionChicago, USA, 02 June 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today presents updated data from its Phase II

Elkem Iceland celebrates 40-year anniversary

Akranes, 1 June 2019: Today, Elkem Iceland celebrates its 40-year anniversary. The plant, located in Akranes - 40 kilometers north of the capital of Reykjavik (IS), is one of the world’s largest ferrosilicon plant in the world, focused on sustainable production of high quality, specialty ferrosilicon.The construction of the plant started in 1977 and the first furnace became operational in 1979. Today Elkem Iceland produces and sells high quality ferrosilicon (FeSi) all around the world. Throughout the years the goal has been to decrease the production of standard FeSi and increase the

Lundin Gold Share Capital and Voting Rights Update

VANCOUVER, BC, May 31, 2019 /CNW/ - Lundin Gold Inc. ("Lundin Gold" or the "Company") (TSX: LUG, Nasdaq Stockholm: LUG) reports the following in accordance with the Swedish Financial Instruments Trading Act:  The Company has 222,734,100 common shares issued and outstanding with voting rights as at May 31, 2019. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the Swedish Financial Instruments Trading Act on disclosure of major

Updated Share Capital and Voting Rights for Lundin Mining

Toronto, May 31, 2019 /CNW/ (TSX: LUN; Nasdaq Stockholm: LUMI) Lundin Mining Corporation (“Lundin Mining” or the “Company”) reports the following, in accordance with the Swedish Financial Instruments Trading Act: The number of issued and outstanding shares of the Company has decreased to 735,456,290 common shares with voting rights as at May 31, 2019. The decrease in the number of issued and outstanding shares from May 1, 2019 to date is a result of the Company purchasing shares under the existing normal course issuer bid (the “NCIB”), partially offset by the exercise of employee stock

Tecnotree Corporation – Managers’ transactions (Kaj Hagros)

Tecnotree CorporationManages’ Transactions31 May 2019 at 11:15 pm (EEST)Person subject to the notification requirementName: Hagros, Kaj PeterPosition: Member of the BoardIssuer: Tecnotree OyjLEI: 743700MRPVY17ASHCX38Notification type: INITIAL NOTIFICATIONReference number: 743700MRPVY17ASHCX38_20190531163401_3 ____________________________________________ Transaction date: 2019-05-29 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009010227 Nature of the transaction: ACQUISITION Transaction details (1): Volume: 4,271 Unit price: .065

Number of shares and votes in Veoneer

Stockholm, Sweden, May 31, 2019: Veoneer, Inc. (NYSE: VNE and SSE: VNE SDB), a pure-play company focused on Advanced Driver Assistance Systems (ADAS) and Automated Driving (AD), today announced the new number of shares and votes in the company.As announced on May 29, 2019 Veoneer has completed a capital raise, resulting in that the number of outstanding shares and votes in Veoneer has changed. Today, the last trading day of the month, there are in total 111,372,130 shares – of which all are shares of common stock – and 111,372,130 votes in the company. This information is information

There are no items matching the current filter
There are no more items matching the current filter
Back to top